Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media


Cosgrove, L., Cristea, I., Shaughnessy, A., Mintzes, B., Naudet, F. BMJ Evidence-Based Medicine 2019;24:231-238

Background In November 2017, the Food and Drug Administration (FDA) approved a version of a second-generation antipsychotic, aripiprazole, embedded with a sensor (Abilify MyCite).
Objective To systematically review the evidence supporting the FDA’s approval of digital aripiprazole and how that evidence was disseminated in the scientific literature and news reports. Read more